Company Description
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable.
Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment.
The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization.
Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment.
The company was founded in 2015 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 10, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 145 |
| CEO | Mathai Mammen |
Contact Details
Address: 30 Acorn Park Drive Cambridge, Massachusetts 02140 United States | |
| Phone | (617) 945-9510 |
| Website | parabilismed.com |
Stock Details
| Ticker Symbol | PBLS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001657677 |
| CUSIP Number | 698955101 |
| ISIN Number | US6989551014 |
| Employer ID | 47-4505725 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Mathai Mammen, M.D., Ph.D. | Chairman, Chief Executive Officer and President |
| Fawzi Benzaghou, M.D. | Chief Medical Officer |
| Helen Ho, Ph.D. | Chief Business and Strategy Officer |
| Thomas Kotarakos | Chief Financial Officer |
| Rohin Mhatre, Ph.D. | Chief Technical Operations Officer |
| Teresa Jurgensen, J.D. | General Counsel |
| Alexis Borisy | Director |
| Edward Fitzgerald | Director |
| Rick Klausner, M.D. | Director |
| Alan M. Sebulsky | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 18, 2026 | SCHEDULE 13D | Filing |
| Jun 11, 2026 | 8-K | Current Report |
| Jun 10, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 10, 2026 | 424B4 | Prospectus |
| Jun 10, 2026 | FWP | Free Writing Prospectus |
| Jun 9, 2026 | EFFECT | Notice of Effectiveness |
| Jun 9, 2026 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Jun 9, 2026 | CERT | Certification by an exchange approving securities for listing |
| Jun 9, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 5, 2026 | 8-A12B | Registration of securities |